Day One Biopharmaceuticals Inc
Day One Biopharmaceuticals — FY2025 Earnings Presentation
20 slides from Day One Biopharmaceuticals's earnings presentation, Feb 24, 2026
Slide 1: Fourth Quarter & Full-Year 2025 Financial Results & Corporate Progress
FEBRUARY 2026 Fourth Quarter & Full-Year 2025 Financial Results & Corporate Progress
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation and the accompanying oral commentary contain forward-looking statements that are based on our management’s beliefs and assumptions and on information currently available to our management. Forward-looking statements are inherently subject to risks and unc
Slide 3: Agenda & Day One Participants
Agenda & Day One Participants Opening Remarks Jeremy Bender (Chief Executive Officer) OJEMDATM 3-Year Data Summary Michael Vasconcelles (Head of R&D) R&D Overview Michael Vasconcelles (Head of R&D) Financial Performance Charles York (Chief Operating & Chief Financial Officer) Q&A Session All Partici
Slide 4: Opening Remarks
Opening Remarks Jeremy Bender Chief Executive Officer
Slide 5: Q4 & FY 2025 – A Transformational Year For Day One
Q4 & FY 2025 – A Transformational Year For Day One EMA: European Medicines Agency 1 Represents the comparison of full year 2024 (April 2024 approval) to full year 2025. 2 Regulatory submission process executed by Ipsen. 3 Represents cash, cash equivalents and short-term investments as of December 31
Slide 6: OJEMDA 3-Year Data Summary
OJEMDA 3-Year Data Summary Michael Vasconcelles Head of R&D
Slide 7: Consistent Safety Profile Through Years of FIREFLY-1 Follow-Up
Consistent Safety Profile Through 3 Years of FIREFLY-1 Follow-Up June 6, 2025 data cutoff. Adverse events were cumulative events from day 1 to the earliest of (last dose + 30 days, start date of subsequent anticancer treatment, data cut, end of study). *TRAEs reported at grade ≥3 in ≥5% of patients.
Slide 8: Meaningful and Durable Responses Maintained with Extended Follow-Up
Meaningful and Durable Responses Maintained with Extended Follow-Up June 6, 2025 data cutoff. *1 patient of 77 had a target lesion not meeting the minimum size at baseline per IRC. †ORR for RAPNO included MRs (i.e., ORR=CR+PR+MR). For CR, PR, and MR, confirmation of response by a subsequent scan app
Slide 9: Endpoints Designed to Reflect Real-World Treatment Decisions
Endpoints Designed to Reflect Real-World Treatment Decisions June 6, 2025 data cutoff. *A cycle was counted if a patient had at least 1 dose in a cycle; patients were treated for a planned period of 26 cycles, after which they could continue tovorafenib or opt to enter an observation period. †1 pati
Slide 10: Clinical Decision-Making Extends Beyond Radiographic PFS in pLGG
Clinical Decision-Making Extends Beyond Radiographic PFS in pLGG June 6, 2025 data cutoff. *1 patient of 77 had a target lesion not meeting the minimum size at baseline per IRC. †Time to next treatment: an exploratory composite endpoint of time from the date of the first tovorafenib dose to the star
Slide 11: OJEMDA Performance
OJEMDA Performance Lauren Merendino Chief Commercial Officer
Slide 12: Commercial Execution and Clinical Impact Driving Strong Revenue Growth
Commercial Execution and Clinical Impact Driving Strong Revenue Growth ~36% Q2 Q3 Q4 Q1 Q2 Q3 Q4 2024 2025 OJEMDA Net Product Revenue $155.4M (+172%)1 in 2025 CQGR Launch $52.8 (+37%)2 $Millions OJEMDA Prescriptions (TRx) 4,635 (+181%)1 in 2025 ~34% Q2 Q3 Q4 Q1 Q2 Q3 Q4 2024 2025 CQGR Launch 1,394 (
Slide 13: Commercial Execution Driving Strong 2026 OJEMDA Outlook
Commercial Execution Driving Strong 2026 OJEMDA Outlook >50% growth represents the comparison of 2025 to the midpoint of 2026 U.S. net product revenue guidance. 1 2024 net revenue included approximately $3.0M of revenue associated with Ex-U.S. sales. FF-1 3-Year Follow-Up Data Fuels Expected 2026 Gr
Slide 14: Our Strategy: Focused Execution to Solidify OJEMDA as 2L Standard of Care
Our Strategy: Focused Execution to Solidify OJEMDA as 2L Standard of Care * On label patients only. Drive New Patient Starts Optimize Persistence Increase depth of prescribing through continued evidence generation that reinforces how OJEMDA’s clinical profile and benefits align with attributes physi
Slide 15: R&D Overview
R&D Overview Michael Vasconcelles Head of R&D
Slide 16: Emi-Le Program Overview
Emi-Le Program Overview 1 Adenoid Cystic Carcinoma Research Foundation, 2 includes both frontline and relapsed ACC. ACC patient population1,2 Investigational B7-H4-targeted ADC Mechanism and modality well matched to ACC biology due to highly and uniformly overexpressed B7-H4 Evidence of monotherapy
Slide 17: DAY301 Program Overview
DAY301 Program Overview 1 Damelin M, et al. Sci Transl Med. 2017;9(372):eaag2611, 2 Devang N, et al. Adv Protein Chem Struct Biol. 2021;124:121–185, 3 Dessaux C, et al. Oncogene. 2024;43(26):1973–1984; 4 https://www.proteinatlas.org/ Accessed May 2025, 5 Lhoumeau A-C, et al. Cell Cycle. 2011;10(8):1
Slide 18: Financial Performance
Financial Performance Charles York Chief Operating Officer & Chief Financial Officer
Slide 19: Fourth Quarter & Full Year 2025 Financial Results
All financial information is unaudited. 1 Includes stock-based compensation expense of $3.4 million and $14.2 million for the three and twelve months ended 12/31/25, and $3.5 million and $16.7 million for the three month and twelve months ended 12/31/24. 2 Includes stock-based compensation expense o
Slide 20: Thank You
Thank You
Day One Biopharmaceuticals — FY2025 Earnings Presentation on 6ix